Incyte presents at the Morgan Stanley 24th Annual Global Healthcare Conference today, September 16, 2026.
Cantor Fitzgerald recently reiterated a Neutral rating on the company. Dermatologists provided positive feedback regarding potential off-label use for the drug Opzelura.
Simply Wall St analysis suggests the company's stock may be overvalued. Recent positive funding news for the cancer treatment MINJUVI in Ontario could bolster future revenue sentiment.
NewEdge Advisors increased its stake in Incyte by nearly 70% during the second quarter.